ArticleThe Journal of nutrition2026
Body Mass Index Subclassification and Future Risk of Metabolic Dysfunction-Associated Steatotic Liver Disease and Liver-Related Events.
Article in The Journal of nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between BMI-discordances in cardiometabolic biomarkers and risk of incident heart failure: a prospective cohort study.The American journal of clinical nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent research using a data-driven cluster approach has identified 5 discordant subclassifying body mass index (BMI) subgroups, characterized by cardiometabolic biomarkers deviated from those predicted by BMI.
objectivesThis study aimed to investigate the associations of these subgroups with risks of metabolic dysfunction-associated steatotic liver disease (MASLD) and liver-related events (LREs).
methodsThis prospective cohort study included 423,091 participants. The same cluster analysis as reported by Coral et al. was performed to classify subpopulations. Incident MASLD and LREs were determined by electronic health records. Cox proportional hazards models were used to evaluate the hazard ratio (HR) and 95% confidence interval (CI).
resultsProfiles derived from the study were similar to those identified in the work by Coral et al. Individuals with discordantly high liver transaminase [HR (95% CI): 1.72 (1.51, 1.96) for MASLD and 1.42 (1.23, 1.65) for LREs in males and 1.92 (1.61, 2.28) for MASLD and 1.68 (1.32, 2.14) for LREs in females] and hyperglycemia [HR (95% CI): 1.36 (1.06, 1.74) for MASLD and 1.31 (1.01, 1.70) for LREs in males and 1.62 (1.27, 2.08) for MASLD and 1.80 (1.31, 2.47) for LREs in females] had higher risks of liver outcomes compared with the concordant profile. In contrast, we observed a lower risk of MASLD [HR (95% CI): 0.71 (0.60, 0.84)] in females with discordantly high blood pressure relative to their BMI. For discordant adverse lipid profile and discordant inflammatory profile, no significant associations were observed. In addition, the BMI subclassification profiles had better predictive ability among males.
conclusionsMetabolically distinct BMI subgroups exhibit heterogeneous risks of MASLD and LREs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.